Mounjaro vs Zepbound: Complete Comparison

Mounjaro and Zepbound are not two different drugs. They are the same molecule — tirzepatide — manufactured by the same company (Eli Lilly), delivered via the same injection pen, and working through the same dual GIP/GLP-1 receptor agonist mechanism. The difference is a label: Mounjaro is FDA-approved for type 2 diabetes, Zepbound is FDA-approved for chronic weight management. And yet, that label determines your insurance coverage, your out-of-pocket cost, what your doctor can legally prescribe for your specific condition, and whether your pharmacy can fill the script.

This is the second time we have seen this exact scenario in the GLP-1 space — Novo Nordisk did it first with Ozempic (diabetes) and Wegovy (weight management), both semaglutide. Eli Lilly followed the same playbook with tirzepatide. Understanding the differences between Mounjaro and Zepbound is less about pharmacology and more about navigating the regulatory and insurance landscape.

The Same Drug, Literally

Tirzepatide is a 39-amino-acid synthetic peptide that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. It is modified with a C-20 fatty diacid moiety that enables albumin binding and extends its half-life to approximately 5 days, allowing once-weekly dosing.

[CITATION: PubMed study needed on tirzepatide molecular structure and pharmacokinetic profile]

Whether the pen says Mounjaro or Zepbound, the tirzepatide inside is identical — same manufacturing facility, same formulation, same stability profile, same injection device. The only differences are regulatory and commercial.

For a complete pharmacological profile of the molecule, see our tirzepatide peptide guide. For how tirzepatide compares to semaglutide, see our tirzepatide vs semaglutide comparison.

Head-to-Head Comparison

The Regulatory Distinction That Matters

Mounjaro: The Diabetes Label

Mounjaro was approved in May 2022 based on the SURPASS clinical trial program, which studied tirzepatide in adults with type 2 diabetes. The SURPASS trials demonstrated:

• HbA1c reductions of 1.9-2.4% depending on dose and comparator
• Weight loss of 7.5-12.9% as a secondary endpoint
• Superior glycemic control compared to semaglutide 1mg (SURPASS-2), insulin degludec (SURPASS-3), and insulin glargine (SURPASS-4)

[CITATION: PubMed study needed on SURPASS trial program results for tirzepatide in type 2 diabetes]

For diabetes patients, Mounjaro offers both excellent glycemic control and significant weight loss — a combination that made it the fastest-growing diabetes drug in FDA history.

Zepbound: The Weight Management Label

Zepbound was approved in November 2023 based on the SURMOUNT clinical trial program, which studied tirzepatide specifically for weight management:

SURMOUNT-1: 20.9% average weight loss with tirzepatide 15mg vs. 3.1% with placebo in adults with BMI of 30 or higher (or 27 or higher with comorbidity) without diabetes.

SURMOUNT-2: 14.7% weight loss in adults with obesity and type 2 diabetes.

SURMOUNT-3: Combined with intensive behavioral therapy, tirzepatide produced an additional 18.4% weight loss beyond what was achieved during a 12-week lead-in lifestyle intervention.

SURMOUNT-4: Demonstrated that continued tirzepatide treatment maintained weight loss, while switching to placebo resulted in weight regain.

[CITATION: PubMed study needed on SURMOUNT 1-4 trial results for tirzepatide in weight management]

The SURMOUNT data established tirzepatide as the most effective anti-obesity medication available, surpassing semaglutide's STEP trial results by approximately 6 percentage points in average weight loss.

Why Two Products Exist

The pharmaceutical industry's practice of launching the same molecule under different brand names for different indications is driven by regulatory strategy, not pharmacology:

1. Regulatory pathway: The FDA requires separate clinical trial programs for each therapeutic indication. Diabetes approval requires demonstrating glycemic efficacy; obesity approval requires demonstrating sustained weight loss. Different NDAs (New Drug Applications), different labels, different approved patient populations.

1. Insurance and pricing: The insurance infrastructure in the United States treats different indications differently. Diabetes medications are broadly covered by commercial insurance and Medicare Part D. Weight-loss medications historically have not been. By maintaining separate products, Lilly can negotiate formulary placement independently for each indication.

1. Marketing: Different patient populations, different provider audiences (endocrinologists vs. obesity medicine specialists vs. primary care), different direct-to-consumer messaging.

1. Regulatory requirements for off-label promotion: Pharmaceutical companies cannot legally promote a drug for uses not approved by the FDA. Having Zepbound as a separate product with a weight-management label allows Lilly to market tirzepatide for weight loss directly.

Pricing and Access

List Prices

Both Mounjaro and Zepbound carry the same list price of approximately $1,060/month across all dose levels. This pricing parity is notable — Novo Nordisk priced Wegovy approximately $400/month higher than Ozempic, but Lilly chose to keep its two tirzepatide brands at the same price point.

Eli Lilly's Access Strategy

Lilly has been more aggressive than Novo Nordisk in creating direct access pathways:

LillyDirect: A direct-to-patient program that offers Zepbound through an integrated telehealth and pharmacy platform, often at prices below insurance copays for patients without coverage.

Single-dose vials: Lilly introduced lower-dose single-use vials of Zepbound (2.5mg and 5mg) at reduced prices, designed for patients starting treatment or maintaining on lower doses.

Savings cards: For commercially insured patients, Lilly's savings card can reduce copays to as little as $25/month for both Mounjaro and Zepbound. These programs do not apply to government insurance (Medicare, Medicaid, Tricare).

Insurance Coverage

Mounjaro for type 2 diabetes: Broadly covered by commercial insurance. Most major PBMs (pharmacy benefit managers) include Mounjaro on their formularies for T2D. Prior authorization is common but generally approvable with documentation of inadequate glycemic control.

Zepbound for weight management: Coverage is expanding but remains inconsistent. As of early 2026, approximately 40-50% of commercially insured lives have access to anti-obesity medication coverage that includes Zepbound. Medicare Part D does not cover weight-loss drugs.

Mounjaro for weight loss (off-label): Using Mounjaro off-label for weight loss in patients without diabetes is common but carries risks — insurance may audit and deny claims, and pharmacies may flag the prescription.

Compounded Tirzepatide

The compounded tirzepatide market is smaller than the compounded semaglutide market, partly because tirzepatide is a more complex molecule to synthesize and partly because its patent and shortage status differ. Compounded tirzepatide is available from select 503A and 503B pharmacies at $200-$500/month. Quality variation is significant — TriedRx testing data shows wider potency variability for compounded tirzepatide than for compounded semaglutide.

For more on compounding pharmacy quality, see our 503A vs 503B comparison.

Practical Considerations

Which Should Your Doctor Prescribe?

The answer depends on your diagnosis:

• If you have type 2 diabetes: Mounjaro is the appropriate prescription. It is FDA-approved for your condition, broadly covered by insurance, and the SURPASS data supports its use for glycemic control.

• If your primary goal is weight management and you do not have diabetes: Zepbound is the appropriate prescription. It is FDA-approved for chronic weight management, supported by the SURMOUNT data, and is the labeled product for this purpose.

• If you have both type 2 diabetes and want weight loss: Both could be appropriate. Some providers prescribe Mounjaro because insurance coverage is easier to secure, with weight loss as a benefit of the diabetes treatment. Others prescribe Zepbound if the patient's primary concern is weight and they have separate diabetes management.

Can You Switch Between Them?

Switching between Mounjaro and Zepbound is pharmacologically trivial — it is the same drug at the same doses. The switch is purely administrative: new prescription, new prior authorization, potentially new insurance coverage determination. Your provider may recommend switching if one product becomes covered by your insurance when the other is not.

Dose Equivalence

The doses are identical:

There is no pharmacological reason to prefer one brand's dose over the other at any level.

The Verdict

Best Overall: Zepbound. For the majority of patients seeking tirzepatide for weight management — which is the primary driver of interest in this drug class — Zepbound is the correctly indicated product, backed by the SURMOUNT trial data, and Lilly's LillyDirect program provides competitive access even without insurance coverage.

Best Value: Mounjaro. For patients with type 2 diabetes, Mounjaro offers the same drug with broader insurance coverage. The weight loss is a welcome secondary benefit. For patients who can secure Mounjaro coverage through a diabetes diagnosis, it provides the same molecule at a potentially lower out-of-pocket cost.

Best Quality: Zepbound. While the drug is identical, Zepbound's label carries the SURMOUNT weight-management data, Lilly's newer access programs (LillyDirect, single-dose vials), and is the product specifically developed and studied for the indication most patients are seeking.

The honest truth is that Mounjaro and Zepbound are a regulatory fiction — two names for one drug, existing as separate products because of how the FDA approval process and insurance reimbursement system work in the United States. The molecule does not care what the label says. Your insurance company does.

For more on how tirzepatide compares to semaglutide, see our tirzepatide vs semaglutide comparison. For the next generation of weight-loss peptides, see our retatrutide vs tirzepatide comparison.